[HTML] nature.comFull View

[HTML][HTML] The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma

M Pan, WC Wright, RH Chapple, A Zubair… - Nature …, 2021 - nature.com
Survival in high-risk pediatric neuroblastoma has remained around 50% for the last 20
years, with immunotherapies and targeted therapies having had minimal impact. Here, we …
Save Cite Cited by 58 Related articles

The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma

M Pan, WC Wright, R Chapple, A Zubair, M Sandhu… - bioRxiv, 2021 - biorxiv.org
Survival in high-risk pediatric neuroblastoma has remained around 50% for the last 20
years, with immunotherapies and targeted therapies having had minimal impact. Here, we …
Cite

The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma.

M Pan, WC Wright, RH Chapple, A Zubair… - Nature …, 2021 - europepmc.org
Survival in high-risk pediatric neuroblastoma has remained around 50% for the last 20
years, with immunotherapies and targeted therapies having had minimal impact. Here, we …
Cite

The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma

M Pan, WC Wright, RH Chapple, A Zubair… - Nature …, 2021 - ideas.repec.org
Survival in high-risk pediatric neuroblastoma has remained around 50% for the last 20
years, with immunotherapies and targeted therapies having had minimal impact. Here, we …
Cite

The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma

M Pan, WC Wright, RH Chapple… - Nature …, 2021 - pubmed.ncbi.nlm.nih.gov
Survival in high-risk pediatric neuroblastoma has remained around 50% for the last 20
years, with immunotherapies and targeted therapies having had minimal impact. Here, we …
Cite

The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma

M Pan, WC Wright, RH Chapple… - Nature …, 2021 - scholars.northwestern.edu
Survival in high-risk pediatric neuroblastoma has remained around 50% for the last 20
years, with immunotherapies and targeted therapies having had minimal impact. Here, we …
Cite
[HTML] nih.gov

[HTML][HTML] The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma

M Pan, WC Wright, RH Chapple, A Zubair… - Nature …, 2021 - ncbi.nlm.nih.gov
Survival in high-risk pediatric neuroblastoma has remained around 50% for the last 20
years, with immunotherapies and targeted therapies having had minimal impact. Here, we …
Cite

The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma.

M Pan, WC Wright, RH Chapple… - Nature …, 2021 - search.ebscohost.com
Survival in high-risk pediatric neuroblastoma has remained around 50% for the last 20
years, with immunotherapies and targeted therapies having had minimal impact. Here, we …
Cite

The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma

M Pan, WC Wright, RH Chapple… - Nature …, 2021 - ui.adsabs.harvard.edu
Survival in high-risk pediatric neuroblastoma has remained around 50% for the last 20
years, with immunotherapies and targeted therapies having had minimal impact. Here, we …
Cite
[PDF] archive.org

[PDF][PDF] TN 38105, USA 20

M Pan, WC Wright, R Chapple, A Zubair, M Sandhu… - scholar.archive.org
Survival in high-risk pediatric neuroblastoma has remained around 50% for the last 20
years, 34 with immunotherapies and targeted therapies having had minimal impact. Here …
Cite